Open Access
Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9
Sergey Brezgin
1, 2
,
Dmitry Zarifyan
1
,
Anastasiya Utkina
1
,
Irina Goptar
1, 3
,
Vladimir Chulanov
1, 4
Тип публикации: Journal Article
Дата публикации: 2019-02-12
scimago Q1
wos Q1
БС1
SJR: 0.874
CiteScore: 6.7
Impact factor: 3.9
ISSN: 20452322
PubMed ID:
30755668
Multidisciplinary
Краткое описание
Chronic hepatitis B is a severe liver disease caused by hepatitis B virus (HBV) infection. Covalently closed circular DNA (cccDNA), a super-spiralized, double-stranded form of the HBV genome, is the major determinant of viral persistence. CRISPR/Cas9 nucleases have been recently shown to introduce double-stranded DNA breaks into HBV cccDNA. The inflicted damage results predominantly in erroneous repair of cccDNA by non-homologous end-joining (NHEJ). NHEJ has been suggested to enhance anti-HBV activity of CRISPR/Cas9 and increase cccDNA mutation. In this study, we assessed anti-HBV activity of CRISPR/Cas9 and cccDNA repair outcomes in an altered NHEJ/HR environment. NU7026, a strong inhibitor of NHEJ, prevented CRISPR/Cas9-mediated degradation of cccDNA and resulted in frequent on-target deletions. We conclude that CRISPR/Cas9 is a highly effective tool to degrade cccDNA and first demonstrate that inhibiting NHEJ impairs cccDNA degradation.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Найдено
Ничего не найдено, попробуйте изменить настройки фильтра.
Топ-30
Журналы
|
1
2
3
4
5
6
|
|
|
International Journal of Molecular Sciences
6 публикаций, 13.04%
|
|
|
Viruses
3 публикации, 6.52%
|
|
|
Microorganisms
2 публикации, 4.35%
|
|
|
Molecular Biology
2 публикации, 4.35%
|
|
|
Frontiers in Genetics
2 публикации, 4.35%
|
|
|
Molecular Therapy - Nucleic Acids
2 публикации, 4.35%
|
|
|
Nucleic Acid Therapeutics
1 публикация, 2.17%
|
|
|
Hepatology Communications
1 публикация, 2.17%
|
|
|
Journal of Clinical Medicine
1 публикация, 2.17%
|
|
|
Genes
1 публикация, 2.17%
|
|
|
Frontiers in Cellular and Infection Microbiology
1 публикация, 2.17%
|
|
|
Cellular and Molecular Biology Letters
1 публикация, 2.17%
|
|
|
Oncogene
1 публикация, 2.17%
|
|
|
Biomedicine and Pharmacotherapy
1 публикация, 2.17%
|
|
|
BioImpacts
1 публикация, 2.17%
|
|
|
Molecular Immunology
1 публикация, 2.17%
|
|
|
IUBMB Life
1 публикация, 2.17%
|
|
|
Cell Biochemistry and Function
1 публикация, 2.17%
|
|
|
Immunity, inflammation and disease
1 публикация, 2.17%
|
|
|
Expert Opinion on Therapeutic Targets
1 публикация, 2.17%
|
|
|
Virulence
1 публикация, 2.17%
|
|
|
Progress in Molecular Biology and Translational Science
1 публикация, 2.17%
|
|
|
Advances in Experimental Medicine and Biology
1 публикация, 2.17%
|
|
|
World Journal of Hepatology
1 публикация, 2.17%
|
|
|
Clinics in Liver Disease
1 публикация, 2.17%
|
|
|
Current Molecular Medicine
1 публикация, 2.17%
|
|
|
International Review of Cell and Molecular Biology
1 публикация, 2.17%
|
|
|
Biochimica et Biophysica Acta - Molecular Cell Research
1 публикация, 2.17%
|
|
|
Infection, Genetics and Evolution
1 публикация, 2.17%
|
|
|
Frontiers in Genome Editing
1 публикация, 2.17%
|
|
|
1
2
3
4
5
6
|
Издатели
|
2
4
6
8
10
12
14
|
|
|
MDPI
14 публикаций, 30.43%
|
|
|
Elsevier
11 публикаций, 23.91%
|
|
|
Wiley
4 публикации, 8.7%
|
|
|
Frontiers Media S.A.
4 публикации, 8.7%
|
|
|
Springer Nature
4 публикации, 8.7%
|
|
|
Pleiades Publishing
2 публикации, 4.35%
|
|
|
Taylor & Francis
2 публикации, 4.35%
|
|
|
Mary Ann Liebert
1 публикация, 2.17%
|
|
|
Maad Rayan Publishing Company
1 публикация, 2.17%
|
|
|
Baishideng Publishing Group
1 публикация, 2.17%
|
|
|
Bentham Science Publishers Ltd.
1 публикация, 2.17%
|
|
|
Institute of Biochemistry
1 публикация, 2.17%
|
|
|
2
4
6
8
10
12
14
|
- Мы не учитываем публикации, у которых нет DOI.
- Статистика публикаций обновляется еженедельно.
Вы ученый?
Создайте профиль, чтобы получать персональные рекомендации коллег, конференций и новых статей.
Метрики
46
Всего цитирований:
46
Цитирований c 2024:
12
(26%)
Цитировать
ГОСТ |
RIS |
BibTex
Цитировать
ГОСТ
Скопировать
Kostyushev D. et al. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9 // Scientific Reports. 2019. Vol. 9. No. 1. 1847
ГОСТ со всеми авторами (до 50)
Скопировать
Kostyushev D., Kostyusheva A., Brezgin S., Zarifyan D., Utkina A., Goptar I., Chulanov V. Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9 // Scientific Reports. 2019. Vol. 9. No. 1. 1847
Цитировать
RIS
Скопировать
TY - JOUR
DO - 10.1038/s41598-019-38526-6
UR - https://doi.org/10.1038/s41598-019-38526-6
TI - Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9
T2 - Scientific Reports
AU - Kostyushev, Dmitry
AU - Kostyusheva, Anastasiya
AU - Brezgin, Sergey
AU - Zarifyan, Dmitry
AU - Utkina, Anastasiya
AU - Goptar, Irina
AU - Chulanov, Vladimir
PY - 2019
DA - 2019/02/12
PB - Springer Nature
IS - 1
VL - 9
PMID - 30755668
SN - 2045-2322
ER -
Цитировать
BibTex (до 50 авторов)
Скопировать
@article{2019_Kostyushev,
author = {Dmitry Kostyushev and Anastasiya Kostyusheva and Sergey Brezgin and Dmitry Zarifyan and Anastasiya Utkina and Irina Goptar and Vladimir Chulanov},
title = {Suppressing the NHEJ pathway by DNA-PKcs inhibitor NU7026 prevents degradation of HBV cccDNA cleaved by CRISPR/Cas9},
journal = {Scientific Reports},
year = {2019},
volume = {9},
publisher = {Springer Nature},
month = {feb},
url = {https://doi.org/10.1038/s41598-019-38526-6},
number = {1},
pages = {1847},
doi = {10.1038/s41598-019-38526-6}
}
Лаборатории